Early FDG-PET Predicts Survival Outcomes in Metastatic Breast Cancer: IMPACT-MBC Trial Reveals Rapid Response Imaging as a Powerful Prognostic Tool
The IMPACT-MBC trial demonstrates that performing FDG-PET after just 2 weeks of first-line systemic therapy can accurately identify metastatic breast cancer patients with distinct long-term outcomes, potentially improving treatment decision-making and patient counseling.
